Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974

Real time quantitative PCR.Preprint

Heid, C., Stevens, J., Livak, K. J., & Williams, P. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,180

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767

A novel method for real time quantitative RT-PCR.Preprint

Gibson, U. E., Heid, C., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.995 · Cited by 2,090

ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,617

The EGF receptor family as targets for cancer therapy

Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment

Liu, M., Li, Z., Yang, J., Jiang, Y., Chen, Z., Ali, Z., He, N., & Wang, Z. (2016) · Cell Proliferation · doi:10.1111/cpr.12266 · Cited by 37

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab

Shin, J. W., Kim, S., Ha, S., Choi, B., Kim, S., Im, S., Yoon, T., & Chung, J. (2019) · Biomolecules · doi:10.3390/biom9100629 · Cited by 36

HER‐2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine

Pupa, S. M., Tagliabue, E., Ménard, S., & Anichini, A. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20387 · Cited by 36

A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis

Leung, K.-M., Batey, S., Rowlands, R. J., Isaac, S. J., Jones, P. C., Drewett, V., Carvalho, J., Gaspar, M. A., Weller, S., Medcalf, M., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.127 · Cited by 35

Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies

Rosemblit, C., Datta, J., Lowenfeld, L., Xu, S., Basu, A. B., Kodumudi, K. N., Wiener, D. A., & Czerniecki, B. J. (2018) · Oncotarget · doi:10.18632/oncotarget.25208 · Cited by 37

Cancer Immunotherapy: The Dawn of Antibody Cocktails

Marrocco, I., Romaniello, D., & Yarden, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_2 · Cited by 36

Novel Mutations of Epidermal Growth Factor Receptor in Localized Prostate Cancer

Diah, A. D. (2006) · Frontiers in bioscience · doi:10.2741/1986 · Cited by 35

A Review of Antibody Therapeutics and Antibody-Related Technologies for Oncology

Scallon, B. J., Snyder, L. A., Anderson, G. M., Chen, Q., Li, Y., Weiner, L. M., & Nakada, M. T. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199196.97845.c3 · Cited by 35

Modular anti‐EGFR and anti‐Her2 targeting of SK‐BR‐3 and BT474 breast cancer cell lines in the presence of ErbB receptor‐specific growth factors

Diermeier‐Daucher, S., Breindl, S., Buchholz, S., Ortmann, O., & Brockhoff, G. (2011) · Cytometry Part A · doi:10.1002/cyto.a.21107 · Cited by 34

Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells

Lakshmanan, I., Seshacharyulu, P., Haridas, D., Rachagani, S., Gupta, S., Joshi, S., Guda, C., Yan, Y., Jain, M., Ganti, A. K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3912 · Cited by 34

Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli

Akbari, V., Mir Mohammad Sadeghi, H., Jafrian-Dehkordi, A., Abedi, D., & Chou, C. P. (2014) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-014-1437-0 · Cited by 34

Cardiac toxicity of trastuzumab in elderly patients with breast cancer

Denegri, A., Moccetti, T., Moccetti, M., Spallarossa, P., Brunelli, C., & Ameri, P. (2016) · PubMed Central · doi:10.5167/uzh-128548 · Cited by 34

Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets

Barnes, C. J., & Kumar, R. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023726827771 · Cited by 34

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design

de Goeij, B. E. C. G., Peipp, M., de Haij, S., van den Brink, E. N., Kellner, C., Riedl, T., de Jong, R. N., Vink, T., Strumane, K., Bleeker, W. K., et al. (2014) · mAbs · doi:10.4161/mabs.27705 · Cited by 33

Pertuzumab in HER2-positive breast cancer

Şendur, M. A. N., Aksoy, S., & Altundağ, K. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.728132 · Cited by 33

Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer

Mattos‐Arruda, L. D., & Cortés, J. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0187 · Cited by 34

Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host

Modica, M. D., Tagliabue, E., & Triulzi, T. (2017) · Disease Markers · doi:10.1155/2017/7849108 · Cited by 33

Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors

Pereira, P. M. R., Mandleywala, K., Ragupathi, A., Carter, L. M., Goos, J. A. C. M., Janjigian, Y. Y., & Lewis, J. S. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.225813 · Cited by 33

Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis

Drucker, A. M., Wu, S., Dang, C. T., & Lacouture, M. E. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2157-7 · Cited by 33

Immunological inhibition of carcinogenesis

Spadaro, M., Lanzardo, S., Curcio, C., Forni, G., & Cavallo, F. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0483-7 · Cited by 33

Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma

Wang, Y., Li, H., Liang, Q., Liu, B., Mei, X., & Ma, Y.-J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2722-2 · Cited by 32

Demethoxycurcumin induces apoptosis in HER2 overexpressing bladder cancer cells through degradation of HER2 and inhibiting the PI3K /Akt pathway

Kao, C., Cheng, Y., Yang, M., Cha, T., Sun, G., Ho, C., Lin, Y., Wang, H., Wu, S., & Way, T. (2021) · Environmental Toxicology · doi:10.1002/tox.23332 · Cited by 32

HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes

Robert, N. J., Goertz, H., Chopra, P., Jiao, X., Yoo, B., Patt, D. A., & Antao, V. (2017) · Drugs - Real World Outcomes · doi:10.1007/s40801-016-0102-5 · Cited by 32

Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARγ

Hedvat, M., Jain, A., Carson, D. A., Leoni, L. M., Huang, G., Holden, S., Lu, D., Corr, M., Fox, W., & Agus, D. B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.014 · Cited by 32

Modern Antibody Technology: The Impact on Drug Development

Moroney, S. E., & Plückthun, A. (2005) · Wiley eBooks · doi:10.1002/9783527620982.ch48 · Cited by 32

Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer

Hu, S., Dai, H., Li, T. X., Tang, Y., Fu, W., Yuan, Q., Wang, F., Lv, G., Lv, Y., Fan, X., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.022 · Cited by 31

Targeting HER2 Positive Breast Cancer with Chemopreventive Agents

Wahler, J., & Suh, N. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-015-0040-z · Cited by 31

Molecular Predictive Factors in Patients Receiving Trastuzumab-Based Chemotherapy for Metastatic Disease

Robinson, A. G., Turbin, D. A., Thomson, T., Yorida, E., Ellard, S. L., Bajdik, C. D., Huntsman, D. D., & Gelmon, K. A. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.038 · Cited by 31

Antibody therapy for breast cancer.

Willems, A., Gauger, K., Henrichs, C., & Harbeck, N. (2005) · PubMed · Cited by 31

A Splice Variant of HER2 Corresponding to Herstatin Is Expressed in the Noncancerous Breast and in Breast Carcinomas

Κoletsa, T., Kostopoulos, I. S., Charalambous, E., Christoforidou, B. P., Nenopoulou, E., & Kotoula, V. (2008) · Neoplasia · doi:10.1593/neo.08314 · Cited by 30

Targeting Human Epidermal Growth Factor Receptor Signaling with the Neuregulin's Heparin-binding Domain

Ma, Z., Li, Q., An, H., Pankonin, M. S., Wang, J., & Loeb, J. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.032714 · Cited by 31

Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression

Niu, G. (2007) · Frontiers in bioscience · doi:10.2741/2720 · Cited by 30

Trastuzumab and Antiestrogen Therapy

Ocaña, A., Cruz, J. J., & Pandiella, A. (2006) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000190274.00570.0a · Cited by 30

Pertuzumab for the treatment of ovarian cancer

Langdon, S. P., Faratian, D., Nagumo, Y., Mullen, P., & Harrison, D. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.487062 · Cited by 29

Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer

Kawajiri, H., Takashima, T., Kashiwagi, S., Noda, S., Onoda, N., & Hirakawa, K. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.992418 · Cited by 29

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure

Antonarelli, G., Corti, C., Tarantino, P., Salimbeni, B. T., Zagami, P., Marra, A., Trapani, D., Tolaney, S. M., Cortés, J., & Curigliano, G. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101608 · Cited by 29

Targeting Receptor Tyrosine Kinases in Cancer

Köstler, W. J., & Zielinski, C. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_10 · Cited by 26

Targeting HER Family in HER2-Positive Metastatic Breast Cancer: Potential Biomarkers and Novel Targeted Therapies

Monteiro, I., Madureira, P., de Vasconscelos, A., Pozza, D. H., & de Mello, R. A. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.133 · Cited by 29

Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer

Mattos‐Arruda, L. D., & Cortés, J. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0043-2 · Cited by 29

Somatic pharmacogenomics in cancer

Ikediobi, O. N. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.8 · Cited by 29

ErbB-2 signaling in advanced prostate cancer progression and potential therapy

Miller, D. R., Ingersoll, M. A., & Lin, M. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0009 · Cited by 31

Characterization of Novel Murine Monoclonal Antibodies Directed Against the Extracellular Domain of Human HER2 Tyrosine Kinase Receptor

Kazemi, T., Tahmasebi, F., Bayat, A. A., Mohajer, N., Khoshnoodi, J., Jeddi‐Tehrani, M., Rabbani, H., & Shokri, F. (2011) · Hybridoma · doi:10.1089/hyb.2011.0023 · Cited by 28

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy

Goltsov, A., Deeni, Y., Khalil, H. S., Soininen, T., Kyriakidis, S., Hu, H., Langdon, S. P., Harrison, D. J., & Bown, J. (2014) · Cells · doi:10.3390/cells3020563 · Cited by 28

Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α

Serdar, C. C., Cokol, M., Cingöz, S., Tasan, I., Öztürk, M., & Yağcı, T. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-450 · Cited by 28

Escalating and de-escalating treatment in HER2-positive early breast cancer

Joensuu, H. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.002 · Cited by 28

Promising tumor‐associated antigens for future prostate cancer therapy

Li, Y., Cozzi, P. J., & Russell, P. J. (2009) · Medicinal Research Reviews · doi:10.1002/med.20165 · Cited by 28

FASN, ErbB2-mediated glycolysis is required for breast cancer cell migration

Zhou, L., Jiang, S., Fu, Q., SMITH, K., Tu, K., Li, H., & Zhao, Y. (2016) · Oncology Reports · doi:10.3892/or.2016.4627 · Cited by 28

Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies

Rockberg, J., Schwenk, J. M., & Uhlén, M. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.01.003 · Cited by 28

Current and emerging therapies of HER2-positive metastatic breast cancer

Hernández-Blanquisett, A., Touya, D., Strasser‐Weippl, K., Ruiz, R., Louis, J. S., & Goss, P. E. (2016) · The Breast · doi:10.1016/j.breast.2016.07.026 · Cited by 28

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer

Henegouwen, J. M. V. B., Jebbink, M., Hoes, L. R., van der Wijngaart, H., Zeverijn, L. J., Velden, D. L. V. D., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., van Werkhoven, E. D., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.009 · Cited by 28

Emerging therapies in gastrointestinal cancers

Nautiyal, J. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i46.7440 · Cited by 27

Trastuzumab resistance: all roads lead to SRC

Muthuswamy, S. K. (2011) · Nature Medicine · doi:10.1038/nm0411-416 · Cited by 27

Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3

Sak, M. M., Szymańska, M., Bertelsen, V., Hasmann, M., Madshus, I. H., & Stang, E. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt173 · Cited by 27

ErbB2 IS A TUMOR ASSOCIATED ANTIGEN AND A SUITABLE THERAPEUTIC TARGET IN WILMS TUMOR

Pinthus, J. H., Fridman, E., Dekel, B., Goldberg, I., Kaufman‐Francis, K., Eshhar, Z., Harmelin, A., Rechavi, G., Mor, O., Ramon, J., et al. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000140139.91993.a0 · Cited by 27

Ovarian Cancer: Opportunity for Targeted Therapy

Tagawa, T., Morgan, R. J., Yen, Y., & Mortimer, J. E. (2011) · Journal of Oncology · doi:10.1155/2012/682480 · Cited by 26

Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer

McCormack, P. L. (2013) · Drugs · doi:10.1007/s40265-013-0109-0 · Cited by 26

Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2- Overexpressing Metastatic Breast Cancer

Huang, Y., Fu, P., & Fan, W. (2013) · Current Drug Targets · doi:10.2174/13894501113149990161 · Cited by 26

ErbB2 blockade with Herceptin (trastuzumab) enhances peripheral nerve regeneration after repair of acute or chronic peripheral nerve injury

Hendry, J. M., Alvarez‐Veronesi, M. C., Placheta, E., Zhang, J. J., Gordon, T., & Borschel, G. H. (2016) · Annals of Neurology · doi:10.1002/ana.24688 · Cited by 26

Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model

Yamashita‐Kashima, Y., Shu, S., Yorozu, K., Moriya, Y., & Harada, N. (2017) · Oncology Letters · doi:10.3892/ol.2017.6679 · Cited by 26

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells

Canonici, A., Qadir, Z., Conlon, N. T., Collins, D. M., O’Brien, N. A., Walsh, N., Eustace, A. J., O’Donovan, N., & Crown, J. P. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0556-7 · Cited by 26

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Liu, S., Xie, S. M., Liu, W., Gagea, M., Hanker, A. B., Nguyen, N. T., Raghavendra, A. S., Yang-Kolodji, G., Chu, F., Neelapu, S. S., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01665-w · Cited by 29

Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival

Maly, J. J., & Macrae, E. R. (2014) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s9032 · Cited by 26

Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates

Kaczyńska, A., Świerczyńska, J., & Herman-Antosiewicz, A. (2015) · Nutrition and Cancer · doi:10.1080/01635581.2015.1053498 · Cited by 26

Newer Therapies in Advanced Prostate Cancer

Hegeman, R. B., Liu, G., Wilding, G., & McNeel, D. G. (2004) · Clinical Prostate Cancer · doi:10.3816/cgc.2004.n.025 · Cited by 26

Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo

Pohl, M., Stricker, I., Schoeneck, A., Schulmann, K., Klein‐Scory, S., Schwarte‐Waldhoff, I., Hasmann, M., Tannapfel, A., Schmiegel, W., & Reinacher-Schick, A. C. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0579-3 · Cited by 25

Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers

Waterhouse, B. R., Gijsen, M., Barber, P. R., Tullis, I. D. C., Vojnovic, B., & Kong, A. H. (2011) · Oncotarget · doi:10.18632/oncotarget.313 · Cited by 25

Molecular basis for prostate cancer racial disparities

Singh, R. (2016) · Frontiers in bioscience · doi:10.2741/4493 · Cited by 25

First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer

Araki, K., Fukada, I., Yanagi, H., Kobayashi, K., Shibayama, T., Horii, R., Takahashi, S., Akiyama, F., Ohno, S., & Ito, Y. (2017) · The Breast · doi:10.1016/j.breast.2017.06.015 · Cited by 25

Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study

O’Shaughnessy, J., Robert, N. J., Annavarapu, S., Zhou, J., Sussell, J. A., Cheng, A., & Fung, A. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06137-3 · Cited by 25

HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models

Gameiro, A., Nascimento, C., Correia, J., & Ferreira, F. (2021) · Cancers · doi:10.3390/cancers13092007 · Cited by 28

Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis

Krutilina, R. I., Hartman, K. L., Oluwalana, D., Playa, H. C., Parke, D. N., Chen, H., Miller, D. D., Li, W., & Seagroves, T. N. (2022) · Cancers · doi:10.3390/cancers14215336 · Cited by 26

HER2+ advanced gastric cancer: Current state and opportunities (Review)

Hu, H.-H., Wang, S., Zhao, H., Chen, Z., Shi, X., & Chen, X. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5624 · Cited by 30

Monoclonal antibodies therapies for ovarian cancer

Maggiore, U. L. R., Bellati, F., Ruscito, I., Gasparri, M. L., Alessandri, F., Venturini, P. L., & Ferrero, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.767328 · Cited by 25

A Molecular View of Anti-ErbB Monoclonal Antibody Therapy

Leahy, D. J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.010 · Cited by 25

The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells

Lyu, H., Yang, X. H., Edgerton, S. M., Thor, A. D., Wu, X., He, Z., & Liu, B. (2015) · Oncotarget · doi:10.18632/oncotarget.6404 · Cited by 25

The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer

Wang, Q., Zhang, X., Shen, E., Gao, J., Cao, F., Wang, X., Li, Y., Tian, T., Wang, J., Chen, Z., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.005 · Cited by 25

Expression of erbB receptors mRNA in thyroid tissues

Kato, S., Kobayashi, T., Yamada, K., Nishii, K., Sawada, H., Ishiguro, H., Itoh, M., Funahashi, H., & Nagasaka, A. (2004) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2004.04.016 · Cited by 25

Role of TGFα stimulation of the ERK, PI3 kinase and PLCγ pathways in ovarian cancer growth and migration

Sewell, J. M., SMYTH, J., & Langdon, S. P. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.11.007 · Cited by 25

Expression of NRG1 and its receptors in human bladder cancer

Forster, J. A., Paul, A., Harnden, P., & Knowles, M. A. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.39 · Cited by 24

HER2 targeting near‐infrared photoimmunotherapy for a CDDP‐resistant small‐cell lung cancer

Takahashi, K., Taki, S., Yasui, H., Nishinaga, Y., Isobe, Y., Matsui, T., Shimizu, M., Koike, C., & Sato, K. (2021) · Cancer Medicine · doi:10.1002/cam4.4381 · Cited by 25

A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells

Liu, X., Luan, L., Liu, X., Jiang, D., Deng, J., Xu, J., Yuan, Y., Xing, J., Chen, B.-G., Xing, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292839 · Cited by 27

Two Dimensions in Targeting HER2

Moasser, M. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7652 · Cited by 24

Antibody-based identification of cell surface antigens: targets for cancer therapy

Loo, D. T., & Mather, J. P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.011 · Cited by 24

Monoclonal antibody therapies for solid tumors

Tassev, D. V., & Cheung, N. V. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802715764 · Cited by 24

Osthole Synergizes With HER2 Inhibitor, Trastuzumab in HER2-Overexpressed N87 Gastric Cancer by Inducing Apoptosis and Inhibition of AKT-MAPK Pathway

Yang, Y., Ren, F., Tian, Z., Song, W., Cheng, B., & Feng, Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01392 · Cited by 24

The Extracellular Linker of pro-Neuregulin-α2c Is Required for Efficient Sorting and Juxtacrine Function

Montero, J. C., Barrueco, R. R., Yuste, L., Juanes, P. P., Borges, J., Esparı́s-Ogando, A., & Pandiella, A. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-06-0511 · Cited by 24

Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel

Domenech, J. M. D., Fernández, P. L., Filella, X., Martinez-Fernandez, A., Molina, R., Fernández, E., Alcaraz, A., Codony, J., Gascón, P., & Mellado, B. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm490 · Cited by 24

Differential expression of 37 selected genes in hormone‐refractory prostate cancer using quantitative taqman real‐time RT‐PCR

Fromont, G., Chêne, L., Vidaud, M., Vallancien, G., Mangin, P., Fournier, G., Validire, P., Latil, A., & Cussenot, O. (2004) · International Journal of Cancer · doi:10.1002/ijc.20704 · Cited by 24

Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation

Campone, M., Juin, P. P., André, F., & Bachelot, T. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.04.012 · Cited by 23

Trastuzumab: A New Treatment Option for HER2-Positive Metastatic Gastric and Gastroesophageal Junction Cancer

Lordick, F. (2011) · Future Oncology · doi:10.2217/fon.10.178 · Cited by 23

Pan‐HER—An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand‐induced EGFR homo‐ and heterodimers

Pollmann, S. E., Brix, S., Grandal, M. M., Lantto, J., Horak, I. D., Kragh, M., & Poulsen, T. T. (2016) · International Journal of Cancer · doi:10.1002/ijc.30242 · Cited by 23

Pertuzumab: A New Targeted Therapy for HER 2‐Positive Metastatic Breast Cancer

Malenfant, S. J., Eckmann, K. R., & Barnett, C. M. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1338 · Cited by 23

Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth

Emde, A., Pradeep, C.-R., Ferraro, D. A., Ben‐Chetrit, N., Sela, M., Ribba, B., Kam, Z., & Yarden, Y. (2010) · Oncogene · doi:10.1038/onc.2010.547 · Cited by 23

Phosphoinositides signalling in cancer: Focus on PI3K and PLC

Raimondi, C., & Falasca, M. (2011) · Advances in Biological Regulation · doi:10.1016/j.advenzreg.2011.09.016 · Cited by 24

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer

Umelo, I. A., Noeparast, M., Chen, G., Renard, M., Geers, C., Vansteenkiste, J., Giron, P., Wever, O. D., Teugels, E., & Grève, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6585 · Cited by 23

Pertuzumab for the treatment of breast cancer: a safety review

Gao, J. J., & Swain, S. M. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1167185 · Cited by 23

Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody

Yu, X., Wang, L., Shen, Y., Wang, C., Zhang, Y., Meng, Y., Yang, Y., Liang, B., Zhou, B., Wang, H., et al. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.05.010 · Cited by 23

Can Trastuzumab Be Effective Against Tumors With Low HER2/Neu (ErbB2) Receptors?

Arteaga, C. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5268 · Cited by 23

Targeted therapy for advanced esophagogastric adenocarcinoma

Kordes, S., Cats, A., Meijer, S. L., & van Laarhoven, H. W. M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.10.004 · Cited by 22

Stop signals

Greenwood, E. (2002) · Nature reviews. Cancer · doi:10.1038/nrc892

Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects

Jackson, J. G., Clair, P. S., Sliwkowski, M. X., & Brattain, M. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3106 · Cited by 104

Changes in heregulin β1 (HRGβ1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line

Yoo, J.-Y., & Hamburger, A. W. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00004-5 · Cited by 7

Erb-2/HER2 Oncogene in Breast Cancer: Does Bivalency of Growth Factors Drive Tumorigenicity Through Receptor Heterodimerization

Yarden, Y. (1999) · doi:10.21236/ada382955

Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells

Grunt, T. W., Saceda, M., Martin, M. B., Lupu, R., Dittrich, E., Krupitza, G., Harant, H., Huber, H. P., & Dittrich, C. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630417 · Cited by 70